Phaseline

Targets › TK

TK: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on TK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The Methodist Hospital Research InstituteADV/HSV-tk
Adenoviral vector encoding herpes simplex virus thymidine kinase (HSV-tk) for suicide gene
TKPhase 1GlioblastomaDec 2026

Conditions

Glioblastoma (1)

Modalities

other (1)

Companies

The Methodist Hospital Research Institute (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.